OSE Immunotherapeutics SA (EPA:OSE)
France · Delayed Price · Currency is EUR 2.040
-0.002 (-0.10%)
Oct 23, 2026, 9:16 AM CEST
OSE Immunotherapeutics Ratios and Metrics
Market cap in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 22, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 48 | 115 | 157 | 81 | 123 | 188 | |
Market Cap Growth | -65.84% | -26.38% | 94.71% | -34.73% | -34.26% | 45.49% |
Enterprise Value | 62 | 102 | 125 | 109 | 128 | 184 |
Last Close Price | 2.04 | 5.15 | 7.17 | 4.28 | 6.67 | 10.28 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 22, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | - | - | 4.19 | - | - | - |
Forward PE | - | 11.12 | 2.83 | 93.66 | 93.66 | 93.66 |
PS Ratio | 17.85 | 42.91 | 1.88 | 36.17 | 6.74 | 7.14 |
PB Ratio | 1.73 | 4.16 | 2.46 | 3.51 | 3.78 | 3.92 |
P/TBV Ratio | 1.73 | 4.16 | 2.46 | 3.53 | 3.80 | 3.93 |
P/FCF Ratio | - | - | 3.24 | - | - | - |
P/OCF Ratio | - | - | 3.24 | - | - | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 22, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 22.92 | 38.08 | 1.50 | 49.07 | 6.99 | 7.01 |
EV/EBITDA Ratio | - | - | 2.70 | - | - | - |
EV/EBIT Ratio | - | - | 2.86 | - | - | - |
EV/FCF Ratio | - | - | 2.58 | - | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 22, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 1.31 | 1.31 | 0.72 | 1.99 | 1.37 | 0.78 |
Debt / EBITDA Ratio | - | - | 0.98 | - | - | - |
Debt / FCF Ratio | - | - | 0.95 | - | - | - |
Net Debt / Equity Ratio | 0.49 | 0.49 | -0.20 | 1.18 | 0.59 | 0.07 |
Net Debt / EBITDA Ratio | -0.36 | -0.36 | -0.28 | -1.34 | -1.22 | -0.24 |
Net Debt / FCF Ratio | -0.40 | -0.40 | -0.27 | -1.37 | -1.03 | -0.34 |
Asset Turnover | 0.03 | 0.03 | 0.81 | 0.03 | 0.19 | 0.27 |
Quick Ratio | 1.17 | 1.17 | 3.29 | 1.40 | 1.97 | 2.36 |
Current Ratio | 1.29 | 1.29 | 3.46 | 1.62 | 2.29 | 2.64 |
Return on Equity (ROE) | -82.32% | -82.32% | 86.29% | -82.69% | -44.10% | -30.85% |
Return on Assets (ROA) | -23.10% | -23.10% | 26.54% | -16.53% | -11.93% | -10.45% |
Return on Invested Capital (ROIC) | -81.29% | -81.29% | 81.47% | -45.10% | -35.78% | -32.30% |
Return on Capital Employed (ROCE) | -69.50% | -69.50% | 42.20% | -36.30% | -24.50% | -19.50% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 22, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | -82.89% | -32.64% | 23.88% | -28.56% | -14.39% | -8.98% |
FCF Yield | -71.07% | -29.56% | 30.84% | -24.56% | -15.01% | -5.54% |
Buyback Yield / Dilution | -5.12% | 13.10% | -31.11% | -5.58% | -2.05% | -16.71% |